Figure 2From: Should health insurers target prevention of cardiovascular disease?: a cost-effectiveness analysis of an individualised programme in Germany based on routine data The strategies with the secondary health outcome ‘days until death’ and cost until death in the cost-effectiveness plane with the expansion path. Costs were inflated to the year 2010. Both costs and effects were discounted at 5%. All: KardioPro for all risk groups. CHD: KardioPro for coronary heart disease patients group. High: KardioPro for high-risk group. Medium: KardioPro for medium-risk group. Low: KardioPro for low-risk group. High and CHD: KardioPro for high-risk and coronary heart disease patients groups. Middle, high and CHD: KardioPro for middle-risk, high-risk and coronary heart disease patients groups. Middle and high: KardioPro for middle-risk and high-risk groups. None: KardioPro for none.Back to article page